Request Demo
Recent blog posts
Latest Hotspot
8 min read
NCT07692750 IBI-343 Pancreatic Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07692750 clinical trial report covering IBI-343, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07696377 Obinutuzumab β Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07696377 clinical trial report covering Obinutuzumab β, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07693751 SOT-109 Advanced Colorectal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07693751 clinical trial report covering SOT-109, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07693036 Human umbilical cord mesenchymal stem cell-derived exosomes (Peking University F Diabetes Mellitus, Type 2 Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07693036 clinical trial report covering Human umbilical cord mesenchymal stem cell-derived exosomes (Peking University F, Phase 1/2, endpoints, sponsor,
Latest Hotspot
8 min read
NCT07694765 Tislelizumab Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07694765 clinical trial report covering Tislelizumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07699328 VRN-11 EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07699328 clinical trial report covering VRN-11, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07698587 BM-230 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07698587 clinical trial report covering BM-230, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07697443 ER PROTAC(Chia Tai Tianqing) Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07697443 clinical trial report covering ER PROTAC(Chia Tai Tianqing), Phase 1/2, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07698106 Isunakinra Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07698106 clinical trial report covering Isunakinra, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07698613 Cetuximab Sarotalocan Sodium (Genetical Recombination) Pancreatic adenocarcinoma metastatic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07698613 clinical trial report covering Cetuximab Sarotalocan Sodium (Genetical Recombination), Phase 1/2, endpoints, sponsor, geography, readout timing
Latest Hotspot
8 min read
NCT07697118 Aldesleukin(Assistance Publique Hopitaux De Paris) Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07697118 clinical trial report covering Aldesleukin(Assistance Publique Hopitaux De Paris), Phase 1/2, endpoints, sponsor, geography, readout timing and
Latest Hotspot
8 min read
NCT07701941 Patritumab Deruxtecan Hormone receptor positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07701941 clinical trial report covering Patritumab Deruxtecan, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.